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Abstract
Rationale—Low circulating progenitor cell (PC) numbers and activity may reflect impaired 
intrinsic regenerative/reparative potential, but it remains uncertain whether this translates into a 
worse prognosis.
Objectives—To investigate whether low numbers of PCs associate with a greater risk of 
mortality in a population at high cardiovascular risk.
Methods & Results—Patients undergoing coronary angiography were recruited into two 
cohorts (1, n=502 and 2, n=403) over separate time periods. PCs were enumerated by flow 
cytometry as CD45med+ blood mononuclear cells expressing CD34, with additional quantification 
of subsets co-expressing CD133, VEGFR2 and CXCR4. Coefficient of variation for CD34 cells 
was 2.9% and 4.8%, 21.6% and 6.5% for the respective subsets. Each cohort was followed for a 
mean of 2.7 and 1.2 years, respectively, for the primary endpoint of all-cause death.
There was an inverse association between CD34+ and CD34+/CD133+ cell counts and risk of 
death in Cohort 1 (β=−0.92, p=0.043 and β=−1.64, p=0.019, respectively) that was confirmed in 
Cohort 2 (β=−1.25, p=0.020 and β=−1.81, p=0.015, respectively). Covariate adjusted HRs in the 
pooled cohort (n=905) were 3.54 (1.67-7.50) and 2.46 (1.18-5.13), respectively. CD34+/CD133+ 
cell counts improved risk prediction metrics beyond standard risk factors.
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of Medicine, 1462 Clifton Road NE, Suite 507, Atlanta, GA, 30322, USA, Tel: 404 727 3655, Fax: 404 727 8785, 
aquyyum@emory.edu. 
DISCLOSURES
None
HHS Public Access
Author manuscript
Circ Res. Author manuscript; available in PMC 2016 January 16.
Published in final edited form as:
Circ Res. 2015 January 16; 116(2): 289–297. doi:10.1161/CIRCRESAHA.116.304187.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Conclusion—Reduced circulating PC counts, identified primarily as CD34+ mononuclear cells 
or its subset expressing CD133 are associated with risk of death in individuals with coronary 
artery disease, suggesting that impaired endogenous regenerative capacity is associated with 
increased mortality. These findings have implications for biological understanding, risk prediction 
and cell selection for cell based therapies.
Keywords
Progenitor cells; CD34; flow cytometry; outcomes research; coronary artery disease; risk; 
prognosis; biomarker
INTRODUCTION
Although cardiovascular risk factor-mediated injury to the vascular endothelium is well 
described, little was known about mechanisms underlying regeneration until the pivotal role 
of progenitor cells (PCs) in vascular repair was discovered.1-3 Circulating PCs are 
mononuclear, originate primarily but not exclusively from the bone marrow, have the 
potential to differentiate into several lineages and contribute to vascular repair and 
regeneration.1, 2, 4, 5 CD34+ mononuclear cells from human bone marrow include distinct 
lineages of both hematopoietic (CD34+/CD45med) and non-hematopoietic (mesenchymal) 
progenitors.6 CD34+ cells have greater myocardial reparative potential than unselected 
populations.7 CD133 is a 5-transmembrane antigen marker of primitive stem cells that is lost 
during maturation, and cells expressing both markers (CD34+/CD133+) may be further 
enriched for a vascular PC phenotype.8, 9 While additional expression of vascular 
endothelial growth factor receptor-2 (VEGFR2) has been proposed to identify more 
differentiated PCs, these sub-populations remain difficult to reproducibly quantify compared 
to other more abundant CD34+ populations. Finally, co-expression of CXCR4, which 
promotes homing of PCs to stromal-derived factor-enriched hypoxic environments for 
enhancing repair, may also further characterize PCs with capacity for vascular repair.10
Lower counts and activity of PCs in blood are associated with cardiovascular risk factors 
and vascular dysfunction, with experimental studies suggesting that diminished PC counts 
reflect impaired regenerative potential.11-15 Early studies have reported an increased risk of 
adverse cardiovascular events in subjects with low numbers of circulating PCs. However, 
the majority of associations were driven by procedural endpoints with PCs characterized 
variably as CD34+, CD133+ or CD34+/VEGFR2 dual positive cells.16-18 Whether low 
circulating PC counts increase mortality in subjects at high cardiovascular risk remains 
unclear. We sought to comprehensively examine the prognostic impact of CD34+ enriched 
PCs in subjects with coronary artery disease (CAD) with the hypothesis that low circulating 
PC counts, reflecting reduced cardiovascular regenerative capacity, will be associated with 
greater mortality. As secondary endpoints we also studied the relationship between PCs and 
cardiovascular death and the combined outcome of death and MI.
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METHODS
Study population
Study participants aged 20-90 years were recruited as part of the Emory Cardiovascular 
Biobank, an ongoing prospective cohort of patients enrolled prior to undergoing coronary 
angiography for investigation or management of CAD across three Emory Healthcare sites 
with collection of data on demographic characteristics, medical history, medication use, 
behavioral habits and risk factor prevalence, details of which have been published 
previously.19
Two sub-cohorts were collected under the same protocol, with identical sampling strategies 
and collection methods but separated in time and by a change in cell quantification 
methodology (see below). Cohort 1 (n=502) was enrolled between March 2006 and 
September 2008, while Cohort 2 (n=403) was collected between October 2008 and February 
2011.
Recruited patients were stable at the time of enrollment and undergoing an elective 
procedure, although stable patients with non-ST elevation myocardial infarction, defined 
using international criteria were also included and classified as “Acute MI”.20 Obstructive 
CAD was defined as >50% luminal narrowing in a major epicardial vessel and a Gensini 
score calculated to quantify the burden of CAD. Patients were excluded if they had a history 
of heart transplantation, immunosuppressant use, malignancy, or significant infections. The 
study complies with the declaration of Helsinki and was approved by the Institutional 
Review Board at Emory University with all subjects providing written informed consent.
Follow-up and endpoints
Follow-up was conducted for determination of the primary endpoint of all cause death, and 
the secondary endpoints of cardiovascular death and the composite of all-cause death or MI. 
This was performed by personnel blinded to PC data through telephone interview, chart 
review and linkage with the Social Security Death Index and State records. Cause of death 
was adjudicated by two cardiologists with a third arbitrator in case of disagreement, who 
were all blinded to PC data. Cardiovascular death was defined as death attributable to an 
ischemic cardiovascular cause (fatal MI, stroke, peripheral arterial disease) or sudden death 
due to an unknown but presumed cardiovascular cause in high risk patients. Medical records 
were accessed or requested to validate all self-reported events including MI, which was 
again defined using standard criteria.20
Flow cytometry
Arterial blood was collected via a femoral sheath in EDTA tubes prior to cardiac 
catheterization after an overnight fast. Blood samples were prepared within 4 hours and 
incubated with fluorochrome-labeled monoclonal anti-human mouse antibodies to identify 
surface markers expressed on mononuclear cells before quantification using flow cytometry. 
Further details are given in Supplementary Methods. Of note, preliminary descriptive 
analysis of cohort 1 revealed very low counts of infrequent cell types. Thus for Cohort 2, 
enumeration of PCs was refined by adding a fixed number of counting beads to 300uL 
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whole blood and a lyse-no-wash methodology that reduced cell loss. This improved 
quantification and cell counts were subsequently noted to be higher for each subset 
compared to Cohort 1. Putative circulating PCs were identified in both cohorts through 
expression of the CD34 surface marker on mononuclear cells that were enumerated as 
CD45med+ cells with and without co-expression of CD133 (CD34+/CD133+) and VEGFR2 
(CD34+/VEGFR2 and CD34+/CD133+/VEGFR2+). In Cohort 2, co-expression of an 
additional marker, CXCR4 was also quantified (as CD34+/CXCR4+ and CD34+/CD133+/
CXCR4+). All cell populations were reported as cell counts/μl.
Statistical analysis—Continuous variables are presented as means (SD) or as median 
(IQR) and categorical variables as proportions (%). Cell counts were non-normally 
distributed and were transformed (natural log (cell count+1)) prior to parametric analyses. 
Cell populations were additionally categorized by tertiles, to derive effect estimates and to 
permit pooled analysis of both cohorts. Finally to assess the potential of cell counts for use 
as a biomarker we derived an optimized cut off in Cohort 1 and applied this threshold (as a 
percentile equivalent of the absolute value) in Cohort 2 for validation. The cut point was 
identified using receiver operating characteristic (ROC) analyses and Youden's index 
(Sensitivity – (1-Specificity)) (Supplementary Figure I).
Survival analysis was performed using Cox proportional-hazards regression in models 
adjusted for age and gender. In the pooled cohort, further adjustment was made for body 
mass index (BMI), diabetes, hypertension, low density lipoprotein (LDL), current smoking, 
statin use, glomerular filtration rate (GFR), acute MI at enrollment, left ventricular ejection 
fraction (LVEF) and CAD burden (Gensini Score) all at baseline. Missing covariate data for 
the fully adjusted model (range 0-3%) was imputed and sensitivity analysis with un-imputed 
data found results to be similar. The proportional hazards assumption for Cox models was 
evaluated by plots of Schoenfeld residuals and formal testing (a chi-square test calculated as 
the sum of Schoenfeld residuals), with no significant violations of the assumption found.
The incremental value of PC counts to risk prediction was tested before and after their 
addition (using high v low categorization described above) to a clinical model with 
traditional risk predictors. The C-statistic (AUC), category free net reclassification 
improvement (NRI) and integrated discrimination improvement (IDI) were calculated as 
indices of risk discrimination.21 P values of <0.05 from two-sided tests were considered to 
indicate statistical significance. All statistical analyses were performed using SAS (Cary, 
NC) and SPSS 20.0 (Chicago, IL).
RESULTS
Baseline patient characteristics of the 502 subjects in Cohort 1 and 403 subjects in Cohort 2 
are shown in Table 1. The mean age and gender distribution was similar across cohorts (62.5 
and 62.9 years; males 64.1% and 65.5%). Overall, patient characteristics were reflective of 
typical populations recruited at coronary angiography, with over two thirds reporting 
hypertension and hyperlipidemia and a third with diabetes.
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Reproducibility of PC quantification and correlation between PC subsets
In 20 samples from the Cohort 2 that were repeatedly analyzed on two occasions by the 
same technician, the coefficients of variation of the cell types were: CD34+ 2.9%; CD34+/
CD133+ 4.8%; CD34+/CXCR4+ 6.5% and CD34+/CD133+/CXCR4+ 7.5%. However, 
CD34+/VEGF2R cells and CD34+/CD133+/VEGF2R cells showed poorer reproducibility at 
21.6% and 35.9%. PC counts were generally higher in Cohort 2 due to the refined 
enumeration methods described above. CD34+ and its subset of CD34+/133+ were highly 
correlated with each other in each cohort (Spearman rho = 0.92 and 0.87, for Cohorts 1 & 2 
respectively) with more modest correlations between other cell types (Supplementary Table 
I).
Relationship between PCs and demographic and clinical features
In Cohort 1, lower CD34+ and CD34+/CD133+ cell counts were univariately associated 
with higher age, male gender, impaired renal function, obstructive CAD and history of prior 
MI. Lower CD34+/CD133+ cells were also associated with CAD burden (Gensini Score) 
and history of PAD. The associations between both cell types with age, gender and renal 
function were replicated in Cohort 2 in which there were further modest correlations 
between lower cell counts and lower BMI, higher HDL (inverse) and current smoking 
(Supplementary Tables II & III).
We did not observe consistent associations between any of the studied cell types and other 
cardiovascular risk factors such as diabetes, hypertension or features such as statin use, LV 
function, history of stroke or presence or absence of an acute MI at enrollment.
Relationship between PC populations and adverse outcomes
During a combined 1800 person-years of follow up, there were 71 deaths.
CD34+ and CD34+/CD133+ cells—In cohort 1 (n=502), Cox Regression analysis 
adjusted for age and gender revealed that both CD34+ and CD34+/CD133+ counts were 
inversely associated with the primary end-point of all cause death (p=0.043 and p=0.019, 
respectively) (Table 2). When categorized into tertiles, those subjects in the lowest tertile of 
CD34+ cell counts had a greater than 4.6-fold risk of death compared to those in the highest 
tertile group (HR 4.63 (95% CI, 1.59-13.5)). There was a similar 3-fold increase in the age- 
and gender-adjusted risk of death for those in the lowest tertile of CD34+/CD133+ cell 
counts (HR 3.09 (95% CI, 1.15-8.33)). For both cell types there was a graded increase in 
effect size per tertile (Table 2 & Figure 1).
In Cohort 2 (n=403), the age- and gender-adjusted association between CD34+ and CD34+/
CD133+ counts and the primary endpoint was replicated (p=0.019 and p=0.015, 
respectively)(Table 3). Similarly, those in the lowest tertile of CD34+ cell counts (HR 3.43 
(95% CI, 1.23-9.59)) and those in the lowest tertile of CD34+/CD133+ cells (HR 2.93 (95% 
CI, 1.05-8.21)) had increased risk of death compared to those in the highest tertile of each 
cell type (Table 3).
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In the pooled cohort of 905 subjects, those in the lowest tertile of CD34+ and CD34+/
CD133+ cells had age- and gender-adjusted HRs of 3.87 (95% CI, 1.86-8.06) and 3.06 (95% 
CI, 1.50-6.24) for the primary endpoint of all-cause death when compared to subjects in the 
highest tertile categories (Table 4). After fully adjusting for likely confounders (age, gender, 
BMI, diabetes, hypertension, LDL, Smoking, GFR, statin use, Gensini score, LVEF, AMI), 
these associations persisted with HRs of 3.54 (95% CI, 1.67-7.50) and 2.46 (95% CI, 
1.18-5.13) for CD34+ and CD34+/CD133+ cells, respectively (Table 4).
Significant associations between CD34+ and CD34+/CD133 cell types were also observed 
for the secondary endpoints of cardiovascular death and the composite of death/MI 
combined (Tables 2-4).
CD34+/CD133− (negative) cells—Among the CD34+ population, cells that did not 
express CD133 (CD34+/CD133−) did not show association with risk of all cause death in 
Cohort 1 (p=0.132) or in Cohort 2 (p=0.07).
VEGFR2+ cells—Co-expression of VEGFR2 on CD34+ or CD34+/CD133+ cells was not 
associated with mortality in either cohort (data not shown).
CXCR4+ cells—CXCR4 co-expression enumerated in Cohort 2 (n=403) demonstrated 
marginal association between lower counts of CD34+/CXCR4+ cells and risk of all-cause 
death in age- and gender-adjusted models (p=0.07). Those in the lowest tertile of CD34+/
CXCR4+ cell counts had a HR of 2.77 (95% CI, 1.04-7.39) for risk of death compared to 
those in the top tertile (Supplementary Table IV). Cells co-expressing both CXCR4 and 
CD133 (CD34+/CD133+/CXCR4+) demonstrated similar borderline association with risk of 
death (Supplementary Table IV).
Finally, we also examined the predictive value of all CD133+ and all CXCR4 expressing 
cell counts within the mononuclear cell populations (unselected for CD34) and found that 
they were not significantly associated with mortality (Supplementary Table V).
Sensitivity analyses
There were no interactions when sensitivity analyses were performed for CD34+ cell counts 
with respect to age, gender and risk factors in both cohorts separately (Supplementary Table 
VI). Although there was an interaction for obstructive CAD in Cohort 2 and LV function in 
Cohort 1, this was not consistent interactions across both cohorts. Specifically, the effect of 
CD34+ cells on mortality was not modified by acute MI at enrollment or presence of other 
ischemic conditions (PAD, Stroke).
Risk discrimination testing
To determine the potential of PCs as biomarkers in exploratory analysis, we identified 
thresholds of 0.737 counts/μl for CD34+ cells (37th centile) and 0.504 counts/μl for CD34+/
CD133+ cells (46th centile) using Youden's index for the primary endpoint in Cohort 1 and 
sought to validate these in Cohort 2 (Supplementary Figure I). Counts of CD34+ and 
CD34+/CD133+ cells below the relevant thresholds were associated with increased risk of 
death after adjustment for age and gender (HR 2.15 (95% CI, 1.16-3.97) and HR 3.16 (95% 
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CI, 1.49-6.72)), respectively in Cohort 1. These findings were fully replicated in Cohort 2 
with similar results with risk of death for “low” values of each cell type (HR 2.79 (95% CI, 
1.31-5.96) and HR 3.27 (95% CI, 1.37-7.83)), respectively. In the pooled cohort, a low 
CD34+ count and CD34+/CD133+ count were associated with a HR of 2.24 (95% CI, 
1.37-3.66) and 2.83 (95% CI, 1.57-5.12), respectively, compared to high counts, after full 
adjustment for the aforementioned covariates.
Finally, in the pooled cohort, we tested the incremental value of this threshold driven PC 
count. The C statistic for prediction of death, when compared to a model with clinical risk 
predictors, increased marginally with the addition of CD34+ cells (Δ 0.020, p=0.07) but 
more significantly with the addition of CD34+/CD133+ cells (Δ 0.028, p=0.04). The 
category free NRI and IDI metrics were also significant for a model including CD34+/
CD133+ cell counts compared to clinical model alone (Table 4).
DISCUSSION
In the largest prospective study of patients with CAD phenotyped for circulating PCs to 
date, we demonstrate that low numbers of blood hematopoietic PCs, characterized as CD34+ 
mononuclear cells are predictive of incident risk of all-cause death, independent of other risk 
determinants. Of these, both CD34+ cells and those co-expressing CD133 appear to be the 
most robustly associated with adverse events, such that in two successive cohorts totaling 
over 900 subjects, the risk of death was >2.5-fold greater in those in the lowest compared to 
highest tertile of these cell counts. Furthermore, the CD34+/CD133+ cell count added 
incremental predictive value to clinical risk factors using risk discrimination indices.
The stromal derived factor-1 receptor CXCR4 is required for homing of PCs and identifies 
cells with greater capacity for migration and neo-vascularization.10 However, the association 
between CD34+ cells co-expressing CXCR4 and death was modest and less robust than the 
CD34+ or the CD34+/CD133+ populations. This may be partly because CXCR4 was 
enumerated in only one population.
In addition, and in contrast to other studies, we found no association between CD34+ cells 
co-expressing VEGFR2 and outcomes in either cohort, possibly because of their very low 
frequency and poor reproducibility of measurement.17, 18 In contrast quantification of total 
CD34+ cells and the CD34+/CD133+ subset is more practical and reproducible.
The mechanisms by which reduced circulating PCs are associated with death is unknown, 
but based on experimental data likely represents increased risk due to impaired endogenous 
regenerative and repair capacity. While CD34+ cells are heterogeneous, they are enriched 
for cells expressing endothelial marker genes and form endothelial structures in vitro and in 
vivo.1, 22 Moreover, pro-angiogenic activity is lacking in selected CD34− cells.7 In our 
study, CD34+ cells of interest in the blood were predominantly (>95%) CD45med+, and thus 
largely represent cells of the hematopoietic lineage. Of note, CD34+ cells expressing the 
CD133+ epitope, which are believed to be early or immature PCs, more precisely reflect risk 
than CD34+ cells without the CD133 epitope, that had no association with risk. While the 
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additional expression of VEGFR2 receptor on CD34+/CD133+ cells is often considered to 
define a subset enriched for endothelial PCs, this remains a subject of controversy.8, 23-26
Three smaller studies have previously reported association between various PC subsets and 
cardiovascular outcomes.16-18 In 120 subjects with and without CAD an association between 
CD34+/VEGFR2+ cell counts and adverse events was found with just 11 events.17 This was 
confirmed in a larger study with largely revascularization events.18 Finally, in subjects 
enriched for metabolic syndrome, cardiovascular events were more frequent in those with 
low CD34+ cell counts,16 findings that were confirmed in a meta-analysis.27 These studies 
were generally smaller, more heterogeneous, did not enumerate CD45med+ subsets, assessed 
cardiovascular events that were predominantly revascularization or hospitalizations, and did 
not perform discriminatory analyses. In contrast, our study represents the largest cohort 
phenotyped for PCs using flow cytometry (at the time of collection) and prospectively 
followed for mortality. Additionally, our 2 cohort strategy, separated in time and 
methodology lends further confidence to our findings. Importantly, and in contrast to 
previous studies, our findings were most robust for the CD34+ and CD34+/CD133+ cell 
subsets and not for cells co-expressing VEGFR2.
We and others have previously demonstrated that lower circulating PC counts characterized 
by flow cytometry or cell culture are associated with endothelial dysfunction and established 
risk factors.12, 13 In cross sectional analyses, we confirmed associations between lower PC 
counts and advanced age and impaired renal function.12, 15, 28 We also found that higher 
counts were associated with male gender, higher BMI and lower HDL. Although acute and 
chronic ischemia may influence PC mobilization, we did not observe any associations or 
interactions with acute myocardial infarction at enrolment or prior conditions such as PAD 
or stroke.30, 31
Strengths of our study include (1) a large prospective single center study design to limit 
heterogeneity, (2) use of commonly used high throughput technology (flow cytometry) for 
quantification of PCs by the same technical team, (3) a 2 cohort analysis strategy, and (4) 
exploration of a selection of CD34+ cell sub-populations. The change in methodology 
between the two cohorts may be considered a limitation, but is also a strength in that the 
associations were fully replicated under different measurement settings. Limitations of our 
study are that we only examined a high risk population undergoing angiography, and 
therefore our conclusions may not be applicable to the general population. Absence of 
longitudinal measurements or assessments of cell functionality also limit the conclusions 
that could be drawn about CD34+ cells and their long term impact on health. Finally, the 
observational nature of this analysis does not imply causation and thus further interventional 
studies directly influencing PC levels are required. Studies demonstrating improvements in 
intermediate phenotypes, such as endothelial function with PC mobilization suggest that this 
could be feasible.32
There are important implications of our findings: (1) CD34+ cells that are enriched for bone 
marrow-derived hematopoietic and endothelial progenitors may represent an index of global 
regenerative potential, a view supported by findings of worse prognosis in patients with 
lower numbers of PCs in the settings of acute lung injury, renal failure, and stroke;33-35 (2) 
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Quantification of these cell subtypes could be used to identify those individuals with CHD at 
greatest risk of subsequent events as part of an enhanced risk prediction model, including 
demographic, clinical features and other novel biomarkers; (3) In addition, CD34+ cells 
could also represent a potentially modifiable risk factor and thus a new target for therapeutic 
interventions, a possibility currently under active study;36 (4) Either CD34+ or CD34+/
CD133+ cell counts could be used equally effectively as a ‘biomarker’ of regenerative 
capacity; and (5) These findings could influence cell based therapy by supporting targeted 
selection and harvesting of these particular PC subsets.
In conclusion, we have demonstrated that fewer circulating PCs, identified primarily as 
CD34+ mononuclear cells are associated with risk of death in individuals at high 
cardiovascular risk. Both CD34+ and CD34+/CD133+ subset are predictive of future 
adverse events, and potentially represent endogenous regenerative capacity. These findings 
have implications for biological understanding, risk prediction and cell selection for cell 
based therapies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Nonstandard Abbreviations and Acronyms
PCs Progenitor Cells
HR Hazard ratio
FACS Fluorescence Activated Cell Sorting
VEGFR2 Vascular Endothelial Growth Factor Receptor 2
CXCR4 Chemokine (C-X-C motif) Receptor 4
MI Myocardial Infarction
CAD Coronary Artery Disease
ROC Receiver Operating Characteristic
NRI Net Reclassification Index
IDI Integrated Discrimination Improvement
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Novelty and Significance
What Is Known?
• Circulating progenitor cells play a role in vascular repair and regeneration.
• Mononuclear cells (MNCs) expressing CD34 and CD133 epitopes constitute a 
population of cells enriched for hematopoietic and/or endothelial progenitor 
cells (PCs), and their circulating levels are modulated by risk factors.
What New Information Does This Article Contribute?
• The numbers of circulating MNCs expressing CD34 alone or in combination 
with CD133 are independent predictors of death in patients with coronary heart 
disease (CHD), such that patients in the lowest tertile had 3-fold greater 
mortality compared with those in the highest tertile.
• Circulating PC counts reflect endogenous reparative capacity and are 
independent predictors of survival in CHD.
Although the injurious effects of cardiovascular risk factors in the pathogenesis of 
atherosclerosis are known, the role of innate repair and regeneration in mitigating this 
damage remains to be studied. Since circulating PCs represent endogenous regenerative 
potential, we investigated whether survival in patients with CHD is associated with PC 
levels. In a large cohort of patients with CHD, we found that the circulating numbers of 
MNCs expressing CD34 alone or in combination with CD133, predicted incident death, 
cardiovascular death, and the composite endpoint of death and myocardial infarction. 
After adjusting for relevant risk factors, there was an almost 3-fold increase in mortality 
in those with PC levels in the lowest tertile compared to those in the highest tertile. The 
CD34+/CD133+ cell count added incremental predictive value to clinical risk factors, 
indicating its additive value as a biomarker for risk prediction in patients with CHD. 
Thus, circulating levels of CD34+ and CD34+/CD133+ PCs, are novel predictors of 
survival in CHD, and may be useful biomarkers in risk prediction and potentially targets 
for therapeutic interventions.
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Figure 1. 
Survival curves adjusted for age and gender, for the primary endpoint of death by tertiles of 
CD34+ (upper panel) and CD34+/133+ (lower panel) cell counts. Results are show 
separately for Cohorts 1 and 2 and the combined “pooled” cohort. Colored lines represent 
tertiles of PC counts (Blue=top tertile; Green=middle tertile; Red=bottom tertile). P values 
for effect estimate in Cox regression model.
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Table 1
Baseline Patient Characteristics
Cohort 1 Cohort 2 P value
N 502 403
Age, years 62.5 (11.6) 62.9 (13.2) 0.60
Male, % 64.3 65.6 0.68
Caucasian, % 71.4 69.5 0.52
Body Mass Index (BMI), kg/m2 30.3 (6.7) 29.3 (6.78) 0.03
Hypertension, % 74.2 88.6 <0.001
Systolic BP, mmHg 140.2 (21.8) 141.1 (23.1) 0.55
Hyperlipidemia, % 76.1 73.7 0.36
Total Cholesterol, mg/dL 170.3 (45.8) 163.6 (48.8) 0.04
Low Density Lipoprotein, mg/dL 99.3 (40.6) 95.0 (42.0) 0.12
High Density Lipoprotein, mg/dL 41.9 (13.2) 41.5 (14.2) 0.72
Diabetes Mellitus,% 31.0 33.0 0.43
Current Smoking,% 17.9 16.0 0.44
Prior Myocardial Infarction (MI), % 28.6 23.8 0.10
Prior CABG, % 20.9 19.9 0.70
Prior Heart Failure, % 20.8 23.1 0.38
Prior Peripheral Arterial Disease, % 17.6 10.0 0.001
Prior Stroke, % 8.0 15.2 0.001
Acute MI at Enrollment, % 10.8 10.7 0.98
Left Ventricular Ejection Fraction % 54.5 (11.1) 53.2 (13.0) 0.12
Renal Function (GFR), ml/min 89.4 (38.4) 84.9 (44.6) 0.08
Statin Use, % 79.0 65.0 <0.001
Obstructive CAD >50%, % 67.5 65.1 0.45
Gensini CAD Score, median (range) 10 (0-33.9) 8 (0-34.1) 0.16
PCI or CABG at Enrollment, % 45.9 38.0 0.02
Cell Populations (Counts/uL) *
CD34+ 1.038 (0.63-1.65) 1.833 (1.10-2.75) -
CD34+/CD133+ 0.535 (0.30-0.93) 0.756 (0.48-1.19) -
CD34+/VEGF2R+ 0.051 (0.02-0.10) 0.189 (0.10-0.35) -
CD34+/CXCR4+ n/a 0.974 (0.63-1.53) -
CD34+/CD133+/CXCR4+ n/a 0.398 (0.24-0.67) -
CD34+/VEGFR2+/CXCR4+ n/a 0.180 (0.09-0.34) -
Follow up
Follow up duration, years 2.66 (1.91) 1.18 (0.51) -
All-cause deaths, n (%) 42 (8.4) 29 (7.2) -
Secondary endpoints
Cardiovascular deaths, n (%) 39 (7.8) 25 (6.2) -
Death or non-fatal MI, n (%) 57 (11.3) 35 (8.7) -
Mean (SD) shown unless stated
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GFR – Glomerular Filtration Rate; CAD – Coronary Artery Disease; PCI – Percutaneous Coronary Intervention; CABG – Coronary Artery Bypass 
Grafting
*Cell Counts shown as median (IQR)
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